Sdf-1 Delivery For Treating Ischemic Tissue


A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.

Owners (US)

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Dec 19, 2017
  • Application: Dec 9, 2013
    US US 201314100050 A
  • Priority: Dec 9, 2013
    US US 201314100050 A
  • Priority: Jun 7, 2012
    US US 201213393141 A
  • Priority: Aug 30, 2010
    US US 2010/0047175 W
  • Priority: May 13, 2010
    US US 33421610 P
  • Priority: Aug 28, 2009
    US US 23777509 P

Sign in to the Lens